ROQAF (Roquefort Therapeutics) ROC % : -19.23% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Roquefort Therapeutics ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Roquefort Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was -19.23%.

As of today (2024-12-11), Roquefort Therapeutics's WACC % is -0.22%. Roquefort Therapeutics's ROC % is -26.57% (calculated using TTM income statement data). Roquefort Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Roquefort Therapeutics ROC % Historical Data

The historical data trend for Roquefort Therapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics ROC % Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

ROC %

-33.98

-32.03

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23	Jun24
ROC %	Get a 7-Day Free Trial			-96.88	-73.24	-28.82	-34.91	-19.23

Roquefort Therapeutics ROC % Calculation

Roquefort Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

	ROC % (A: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2022 )	+	Invested Capital (A: Dec. 2023 ))	/ count )
=	-2.448 * ( 1 - 9.73% )	/	( (6.766	+	7.033)	/ 2 )
=	-2.2098096	/	6.8995
=	-32.03 %

where

	Invested Capital		(A: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.462	-	0.083	-	( 2.829	-	max(0, 0.341	-	2.954	+	2.829	))
=	6.766

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.708	-	0.184	-	( 0.68	-	max(0, 0.389	-	0.88	+	0.68	))
=	7.033

Roquefort Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-1.726 * ( 1 - 17.45% )	/	( (7.033	+	7.784)	/ 2 )
=	-1.424813	/	7.4085
=	-19.23 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.708	-	0.184	-	( 0.68	-	max(0, 0.389	-	0.88	+	0.68	))
=	7.033

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.728	-	0.173	-	( 0.758	-	max(0, 1.098	-	0.869	+	0.758	))
=	7.784

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

Roquefort Therapeutics (OTCPK:ROQAF) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Roquefort Therapeutics's WACC % is -0.22%. Roquefort Therapeutics's ROC % is -26.57% (calculated using TTM income statement data). Roquefort Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Roquefort Therapeutics ROC % Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (OTCPK:ROQAF) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

ROQ:UK

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

From GuruFocus

Roquefort Therapeutics PLC at OTC Markets Life Science Investor Forum (Virtual) Transcript

By GuruFocus Research • 03-27-2024